Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Articles|August 25, 2014
2014 Future Pharmacist Category Finalists
This video features the finalists for the 2014 Next-Generation Pharmacistâ„¢ Future Pharmacist of the Year award, presented by Pharmacy Times and Parata Systems.
Advertisement
This video features the finalists for the 2014 Next-Generation Pharmacist™ Future Pharmacist of the Year award, presented by Pharmacy Times and Parata Systems:
- Saswat Kabisatpathy, PharmD, South Carolina College of Pharmacy, Charleston, SC
- Megan E. Saunders, PharmD, University of Wyoming School of Pharmacy, Laramie, WY
- Laura Vollmer, PharmD Candidate 2015, Drake University College of Pharmacy and Health Sciences, Des Moines, IA
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Ramantamig's 93.6% ORR and Outpatient CRS Control
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5